Effect of lifestyle adjustment, metformin and rosiglitazone in polycystic ovary syndrome
Abstract
OBJECTIVE: To compare the efficacy of weight loss, metformin and rosiglitazone in women with polycystic ovary syndrome (PCOS).
METHODS: A randomized controlled trial (RCT) was carried out in Peking Union Medical College Hospital (PUMCH), one hundred and six women with PCOS were assigned to three intervention groups: weight loss, weight loss and metformin, weight loss and rosiglitazone group. Patients were treated with weight loss (diet and exercise), weight loss and metformin (500 mg three times daily), weight loss and rosiglitazone (4 mg once daily) for three months. Sixty patients completed treatments. Basal body temperature (BBT), total testosterone as well as fasting serum insulin levels and lipid were measured and compared in all patients before and after weight loss.
RESULTS: No significant differences were found in the baseline characteristics among three groups. In weight loss group 51% (22/43) patients completed treatment, and 23% (5/22) patients resumed ovulation. In weight loss and metformin group 58% (21/36) patients completed treatment, and 43% (9/21) patients resumed ovulation. In weight loss and rosiglitazone group 63% (17/27) patients completed treatment, and 59% (10/17) patients resumed ovulation. Ovulation rate was significantly higher in weight loss and rosiglitazone group than in weight loss group. There was no significant difference among three groups in body mass index (BMI), waist circumference, waist-hip ratio (WHR), sex hormone, serum fasting insulin…
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design.
Read the paper
Related studies
- Metformin as an adjuvant in breast cancer treatment
- Metformin Lysosomal Targeting: A Novel Aspect to Be Investigated for Metformin Repurposing in Neurodegenerative Diseases?
- Aberrant HSF1 signaling activation underlies metformin amelioration of myocardial infarction in mice
- Metformin induces ZFP36 by mTORC1 inhibition in cervical cancer-derived cell lines
- Protein Interaction Network for Identifying Vascular Response of Metformin (Oral Antidiabetic)
- Preventing Long COVID With Metformin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.